Hutchmed Scores U.S. Success With Cancer Drug, but Profits Still Dip
HUTCHMED (China) Analyst Ratings
Shandong Xinhua Pharmaceutical Company Limited Goes Ex Dividend Monday
Hutchmed Gains as Ipsen-partnered Lymphoma Drug Undergoes Review in China
Why HUTCHMED Stock Is Moving Higher Friday
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration
Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
Reported Earlier, HUTCHMED Initiates The RAPHAEL Registrational Phase III Trial Of HMPL-306 For Patients With IDH1- And/Or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia In China
HUTCHMED Shares Are Trading Higher. The Company on Friday Announced a Positive CHMP Opinion for Fruquintinib.
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
On Wednesday, HUTCHMED Announced Savolitinib SNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
Affimed N.V., Hutchmed, Annexon Among Healthcare Movers
2024 Financial Report | The domestic volume is not as good as the foreign volume. Takeda's down payment helped reverse the loss with Huang Pharmaceutical
Who says innovative drugs don't make money when they go overseas
HUTCHMED Announces That Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HUTCHMED's New Drug Application For Sovleplenib For The Treatment Of Primary Immune Thrombocytopenia Has Been Accepted For Review And Granted Priority Review By The China
HUTCHMED Confirms ELUNATE And SULANDA Remain On China's National Reimbursement Drug List Under Existing Terms
Reported Earlier, HUTCHMED Completes Enrollment Of Phase II/III Trial Of Fruquintinib In Combination With Sintilimab For Advanced Renal Cell Carcinoma In China